IDEXX LABORATORIES INC /DE Accounts Receivable, Allowance for Credit Loss
IDEXX LABORATORIES INC /DE (IDXX) had Accounts Receivable, Allowance for Credit Loss of $15.00 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-04
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $15.00M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $14.30M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $11.30M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $11.70M.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $15.00M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $14.30M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $11.30M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $11.70M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $12.20M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $12.70M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $12.60M 10-K · filed 2026-02-20 |
| 2024-09-30 | $12.40M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $12.30M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $10.60M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $9.50M 10-K · filed 2025-02-21 |
| 2023-09-30 | $10.10M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $9.80M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $9.10M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $8.30M 10-K · filed 2024-02-22 |
| 2022-09-30 | $8.80M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $8.00M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $7.30M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $5.70M 10-K · filed 2023-02-16 |
| 2021-09-30 | $6.50M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $6.40M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $6.70M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $6.80M 10-K · filed 2022-02-16 |
| 2020-09-30 | $6.60M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $7.60M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $7.00M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $3.60M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |